Derek Lewis, MD

CURRICULUM VITAE
Specialists in Family Practice
Board Certified

Personal Biography:  
Place of Birth: Hughes, AR
Date of Birth: April 29, 1956

Post-Graduate Education:  
University of Arkansas for Medical Sciences
Little Rock, AR
Doctor of Medicine
1980-1984

Internship:
University of Arkansas for Medical Sciences
Little Rock, AR
Family Practice
1984-1985

Residency:
University of Arkansas for Medical Sciences
Little Rock, AR
Family Practice
1985-1987

Employment: 
Arkansas Physical Medicine and Rehabilitation
2007 – present
Arkansas Primary Care Clinic, PA
Physician, Owner, CEO
l987 - 2007

Licensure:
Arkansas, # C—663l

Professional Organizations:
Arkansas Foundation for Medical Care (Board Member)
Arkansas Medical Association
Arkansas Academy for Family Physicians
American Academy for Family Physicians
American Cancer Society
National Medical Association
UCA Alumni President
Omega Psi Phi Fraternity

Hospital Affiliations:  
Baptist Medical Center - Obstetric Privilege
St. Vincent Infirmary Medical Center
Columbia Doctors Hospital
Southwest Hospital - Obstetric Privileges

Clinical Research Experience:

Phase II clinical study to compare two investigational formulations of an approved medication in patients with type 2 diabetes. 2000-200l.

Phase IV clinical study in African Americans and Hispanics with type II diabetes. 2001-Present.

Phase IV clinical study to test the effects of two study medications on the liver in patients with type 2 diabetes. 200l-Present.

Phase II clinical study to compare study drug with any SSRI in patients with major depressive disorder. 2001-Present.

Phase III clinical study is African American Subjects with Congestive Heart Failure. 200 l -Present.

Phase IIb clinical study in subjects with isolated systolic hypertension. 2001-Present.

Phase II clinical study in African American subjects with hypertension. 2001-Present.

Phase IIb/III clinical study in subjects with type II diabetes that are treatment naive. 200l-Present

Phase IIIb clinical study in African American subjects with hypertension, 2002-Present.

A Phase 3, Randomized, Three-Arm, Double-Blind, Active-Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of XXX in Combination with YYY Compared to ZZZ in Combination with XXX Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on XXX Therapy Alone, 2004.

A 24-Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral XXX (250mcg or 500mcg) Daily in Patients with Asthma, 2004.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of the Efficacy and Safety of XXX in Type 2 Diabetes with Inadequate Glycemic Control on Metformin Monotherapy, 2004.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of XXX in Type 2 Diabetics with Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy in Combination with Other Oral Anti-Diabetic Agents, 2004.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of XXX in Type 2 Diabetes with Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination with Other Oral Anti-Diabetic Agents, 2004.

An Open-Label Study of the Efficacy and Safety of 5 and 10MG XXX in Patients with Overactive Bladder Symptoms, 2004.

A multicenter, double blind, randomized, placebo controlled study comparing 3 continuous oral XXX (aaa 3mg/ l7·bbb 1mg aaa 2mg/ l7·bbb 1mg/l7·bbb 1mg) combination and l7·bbb (1mg) combinations and l7-bbb (1mg) with placebo for a treatment period of 8 weeks on Ambulatory and Office cuff blood pressure in Postmenopausal women with stage I or stage 2 essential hypertension, 2004.

A one year multinational, multicenter, open labeled, parallel group, 2:1 randomized treat to target comparing efficacy and safety of XXX with YYY rgine using a basal bolgus regimen with XXX as mealtime insulin in subjects with type 2 diabetes, 2004.

A randomized, double blind, double dummy, placebo controlled, 26 week dose response study of XXX with active comparator (YYY) in subjects with type 2 diabetes, 2005.

A randomized, double blind, placebo controlled I2 week study of XXX at doses of 50mg BID, 100mg BID, 200mg BID and YYY 500mg BID in patients with type 2 diabetes, 2005.

A randomized, double blind, placebo controlled, I2 week efficacy and safety study of XXX 200mg BID and 400mg YYY in subjects with type 2 diabetes, 2005.

A multicenter, 52-week, open label extension study to evaluate the long term safety and tolerability of XXX in type 2 diabetic patients, 2005.

A double blind, randomized, placebo and active controlled, forced titration study evaluating the effects of XXX on blood pressure and heart rate in African American patients with hypertension, 2005.

A double blind multicenter active controlled (15, 30 and 45mg XXX) long term extension study to evaluate the safety and tolerability of Oral XXX (0.5 and ling) in patients with type 2 diabetes mellitus, 2005.

A multicenter, randomized, double blind placebo controlled comparison study to determine the efficacy and safety of XXX in patients with type 2 diabetes, who are either receiving no current treatment or currently treated with diet and exercise, a XXX XXX, or a combination of a XXX and XXX, 2005.

A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Comparing XXX 2%, XXX 2% Combination Vaginal Cream with XXX, XXX, and Placebo, 2005.

A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of Co-Administration of XXX Plus XXX Compared to Monotherapy in Patients with Mild to Severe Hypertension, 2005.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of XXX as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise, 2005.

An Open-Label, Randomized Study evaluating the Long-Term effects of XXX Versus XXX as Monotherapy or in Combination with XXX or XXX for the Treatment of Patients with Hypertension, 2005.

A Long-Term, Post treatment, Safety Follow--up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the XXX, XXX, or XXX (Post Treatment Long-Term Follow-Up Study, 2005 .

A 6·Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of XXX and YYY in the Treatment of Hypercholesterolemia in African American Subjects.

A Randomized, Double·Blind, Active-Controlled, Parallel-Group, Single-Dummy, Multicenter, l2 Week Study to Assess to Efficacy and Safety of XXX 160/4.5ug X 2 Actuations Once Daily QD compared to XXX S0/4.5ug X 2 Actuations QD, XXX 80/4.5ug X 2 Actuations twice daily (BID) and to YYY l60ug X 2 Actuations QD in Asthmatic Subjects l2 years of age and older, 2003.

A Phase 3, Randomized, Double-Blind, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of XXX in Combination with YYY Compared to ZZZ in Combination with YYY in Subjects with Type II Diabetes who have Inadequate Glycemic Control on YYY Therapy Alone, 2003.

A Phase 3, Open-Label Study to Assess the Long-Term Safety of Oral XXX in Subjects with Gout, 2003.

A Multicenter, Double-Blind, Placebo·Controlled, Randomized Study of the Safety of XXX in the Treatment of Patients with Type 2 Diabetes Mellitus, 2003.

Study of XXX HCI in Women of Different Demographic Characteristics and C0Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety, 2004.

A Multi-Center, Randomized, Double·Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of 200, 400, and 600 mg/day XXX in Subjects with Painful Distal Diabetic Neuropathy, 2003.

Symptom Specific Effectiveness of XXX 4mg in Patients with Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase IV, Open-Label, Single Ann, NonRandomized Trial in Adult Patients with OAB, 2004.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of XXX 20mg in the primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein, 2004.

Assessment of Efficacy and Tolerance of Infant Formula Containing Prebiotics Fed to Infants, 2004.

A Multicenter, Randomized, Double·Blind, Placebo-Controlled Parallel Study to Determine the Effect of XXX 20MG on LDL-C when Administered Once Daily to Subjects with Moderately Elevated Primary Hypercholesterolemia, 2004.

Clinical Utility of XXX in Simultaneously Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population, 2004.

A Prospective, Randomized, Double-Blind, Parallel Group, Multi-Center, Titration Study Comparing the Safety and Efficacy of XXX Extended Release Tablets (XXX) Taken at Bedtime to YYY Taken in the Morning in Achieving Optimal Blood Pressure Control n African-American Patients with Stage I or Stage II Essential Hypertension. 2002-Present.

A Double-Blind, Randomized Comparison Study of the Safety and Efficacy of the Addition of XXX or Placebo in Reducing or Eliminating Insulin Requirement in Subjects Controlled Insulin and YYY or Insulin Alone Who have Previously Failed Oral Therapy.

A Multi-Center, Parallel Group Extension Study to Determine the Safety and efficacy of Long-Term XXX Exposure in Patients with Mild to Moderate Hypertension.

A Phase III Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral XXX Versus YYY in Subjects with Gout. 2002.

An Evaluation of the Effectiveness of XXX (XXX inhalation suspension) versus YYY (YYY) in Children 2-8 years old with Asthma Requiring Controller Therapy. 2002.

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of an Intravagional Ring Delivering XXX in the Treatment of Bacterial Vaginosis. 2002.

An Evaluation of the Effectiveness of XXX (XXX) Versus YYY (YYY) in Children 2-8 years old with Asthma Requiring Controller Therapy, 2002.

The Efficacy and Safety of XXX for the Treatment of Type II Diabetes, 2003.

A Phase III, Randomized, Multicenter, XXX and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral YYY in Subjects with Gout. 2003.

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Factorial Study of XXX Extended-Release Tablets, YYY and Their Combination in Patients with Essential Hypertension, 2003.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety, and Efficacy Study of XXX in Elderly Subjects with Chronic Insomnia, 2003.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety, and Efficacy Study of XXX in Adult Subjects with Chronic Insomnia, 2003.

A Phase IV, Multicenter, Double-Blind, Randomized, Parallel Group, Dose-Response Study Assess the Effect of Extended Release XXX on Cardiac Remodeling Chronic Heart Failure Patients with Left Ventricular Dysfunction (MD-CHF).

A Multi-center, Double-Blind, Randomized Study to Evaluate the Lipid-Lowering Efficacy, Safety , and Tolerability of XXX Co-administered with YYY Versus YYY Monotherapy in African-American Subjects with Primary Hypercholesterolemia.